Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, Share, Trends, Growth 2032

Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Prospective:

The global duchenne muscular dystrophy (DMD) therapeutics market size was worth around USD 2.13 billion in 2023 and is predicted to grow to around USD 3.76 billion by 2032 with a compound annual growth rate (CAGR) of roughly 6.50% between 2024 and 2032.

Request Free Sample

The report covers forecast and analysis for the Duchenne Muscular Dystrophy (DMD) therapeutics market on a global and regional level. The study provides historic data from 2016 along with a forecast from 2023 to 2032 based on revenue (USD Billion). The study includes drivers and restraints for the Duchenne Muscular Dystrophy (DMD) therapeutics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Duchenne Muscular Dystrophy (DMD) therapeutics market on a global as well as regional level.

Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Growth Drivers

In order to give the users of this report a comprehensive view on the Duchenne Muscular Dystrophy (DMD) therapeutics market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein type segment is benchmarked based on their market size, growth rate and general attractiveness.

Request Free Sample

The report provides company market share analysis in order to give a broader overview of the key players in the Duchenne Muscular Dystrophy (DMD) therapeutics market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the Duchenne Muscular Dystrophy (DMD) therapeutics market on global and regional basis.

Duchenne muscular dystrophy is a harsh kind of muscular dystrophy. The indication of muscle weakness typically begins at the age of four in boys and deteriorates rapidly. Most of the affected people are incapable of walking by the age of 12. The affected muscles tend to look bigger because of augmented fat content. Constant research efforts in comprehending the etiology of Duchenne muscular dystrophy gave way to the recognition of the dystrophin gene that is accountable for coding patients.

Factors such as growing funding for research and development activities and technological advancements in diagnostic techniques will act as major driving factors in the growth of global Duchenne Muscular Dystrophy (DMD) therapeutics market. Efforts taken by governments and non-government organizations to create awareness will act as an opportunity for the market players in the Duchenne Muscular Dystrophy (DMD) therapeutics market. Nonetheless, lack of awareness and dearth of skilled researchers will restrict the growth of global Duchenne Muscular Dystrophy (DMD) therapeutics market.

Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Segmentation

The global Duchenne Muscular Dystrophy (DMD) therapeutics market has been split into type and region.

Based on type, Duchenne Muscular Dystrophy (DMD) therapeutics market has been segmented into small molecules and biologics. The biologics segment accounted for the highest market share in 2018 due to ongoing research on biologics and anticipated launch of biologics currently in late phases of clinical trials.

Duchenne Muscular Dystrophy (DMD) Therapeutics Market : Report Scope

Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Regional Analysis

North America will be the leading region during the forecast period. High investment in research and development of Duchenne Muscular Dystrophy (DMD) therapeutics and presence of major manufacturers will boost the market growth in this region. Europe is expected to be the second major market. The key reasons are efforts taken by health agencies and advantageous reimbursement scenario. Asia Pacific will grow at rapid rate over the forecast time-frame due to increasing investment in research and development to develop new products. The market in Latin America will grow at a substantial rate during the estimate period. The Africa and Middle Eastern region is expected to exhibit definite progression in the anticipated time-frame.

Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Competitive Analysis

The global Duchenne Muscular Dystrophy (DMD) Therapeutics market is led by players like:

• PTC Therapeutics Inc.
• F. Hoffmann-La Roche Ltd.
• Santhera Pharmaceuticals
• Wave Life Sciences Ltd.
• and Sarepta Therapeutics Inc.

This report segments the Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market as follows:

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market: By Type

• Small Molecules
• Biologics

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market: By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa